Samay

Samay Health is a medical technology company established in 2018, focusing on respiratory health. The company is building an AI-driven platform to facilitate the continuous monitoring of patients with chronic respiratory conditions, aiming to replace difficult hospital-based pulmonary tests. The inspiration for the company came from the personal experience of founder and CEO, Dr. Maria Artunduaga, a Colombian-born physician and scientist, who witnessed her grandmother's struggles with Chronic Obstructive Pulmonary Disease (COPD) exacerbations. This motivated Dr. Artunduaga to leave her career in plastic surgery to create a solution to prevent deaths from misdiagnosis.

The company's core product is "Sylvee," a wearable chest patch connected to an AI-powered platform. This system is designed to monitor key respiratory indicators such as pulmonary volumes, trapped air, heart and respiratory rates, and breathing sounds around the clock. The objective is to provide patients and their care teams with actionable insights to manage their respiratory health proactively. By capturing data continuously, the platform can detect early diagnostic biomarkers for COPD and predict exacerbations. Clinical validation has shown the device to achieve accuracy rates of 83% to 99% for various respiratory parameters and 90% accuracy in diagnosing COPD.

Samay operates in the health tech and medical devices market, specifically targeting the 545 million people worldwide affected by chronic respiratory illnesses. Its clients are expected to include pharmaceutical companies, medical technology firms, clinical research organizations (CROs), hospitals, and pulmonary clinics. The business model appears to be centered on the sale of the Sylvee device and its associated data platform. The company has secured over $4 million in capital, with a significant portion coming from U.S. grants, including support from the NHLBI Small Business Innovation Research (SBIR) Program. Samay has won several accolades, including the MedTech Innovator's Grand Prize and was the first Latin American company to win the 2024 Early-Stage Grand Prize at The MedTech Conference. The company holds seven granted patents and projects an annual recurring revenue of $1 million by mid-2026.

Keywords: respiratory health, COPD monitoring, wearable medical device, AI diagnostics, pulmonary function, remote patient monitoring, chronic respiratory disease, health tech, acoustic resonance, digital health, clinical validation, medical device, Sylvee, Maria Artunduaga, exacerbation prediction, continuous monitoring, air trapping, lung health, medtech, AI-powered platform